Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1606 to 1620 of 7712 results

  1. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA975

  2. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    29 August 2024
    View recommendations

    Sections for TA997

  3. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  4. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development

  5. Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension

    In development [GID-IPG10299] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  6. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  7. Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

    In development [GID-IPG10391] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  8. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  9. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

    In development [GID-TA10784] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  10. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  11. Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728

    Awaiting development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)

    Evidence-based recommendations on AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images

    Diagnostics guidance
    Published
    5 July 2023
    View recommendations

    Sections for DG55

  13. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis

    Diagnostics guidance
    Published
    21 June 2017
    View recommendations

    Sections for DG29

  14. Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G)

    Diagnostics guidance
    Published
    15 November 2017
    View recommendations

    Sections for DG31

  15. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (DG39)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the

    Diagnostics guidance
    Published
    17 June 2020
    View recommendations

    Sections for DG39